Isabelle Grillier Vuissoz
Associate Professor in Cell Biology in Lorraine university, UMR CNRS-UL 7039 CRAN( CRAN univ-lorraine.fr).
Research goal: Identification of new therapeutic targets for cancers. KW. Nuclear receptors, TZD, estrogen, claudin 1, apoptosis, migration.
She completed her PhD in university of science, Lille, France in 1994 on the molecular pharmacology of retinoids. Then, she was Post-Doc Researcher at the division of Hematology/Oncology, Department of medicine, U.C.L.A, Cedars-Sinai-Medical-Center, Los Angeles, CA. U.S.A. She studied the mechanism of retinoid resistance in leukemic myeloid cells, and the role of a transcription factor C\ECPε in myeloid cells. In 1997, she was first assistant in animal biology (teacher/researcher), University of Lausanne, Switzerland. She studied the function of PPAR in the neuronal development. In 1999, she jointed university de Lorraine as associate professor. She worked on Estrogenic and Thiazolidinedione signalization in breast cancer in order to identified new therapeutic targets. She is now focused on triple-negative breast tumor, studying the role tumor suppressor of claudin 1, a tight junction protein.
Isabelle Grillier Vuissoz
Associate Professor in Cell Biology in Lorraine university, UMR CNRS-UL 7039 CRAN( CRAN univ-lorraine.fr).
Research goal: Identification of new therapeutic targets for cancers. KW. Nuclear receptors, TZD, estrogen, claudin 1, apoptosis, migration.
She completed her PhD in university of science, Lille, France in 1994 on the molecular pharmacology of retinoids. Then, she was Post-Doc Researcher at the division of Hematology/Oncology, Department of medicine, U.C.L.A, Cedars-Sinai-Medical-Center, Los Angeles, CA. U.S.A. She studied the mechanism of retinoid resistance in leukemic myeloid cells, and the role of a transcription factor C\ECPε in myeloid cells. In 1997, she was first assistant in animal biology (teacher/researcher), University of Lausanne, Switzerland. She studied the function of PPAR in the neuronal development. In 1999, she jointed university de Lorraine as associate professor. She worked on Estrogenic and Thiazolidinedione signalization in breast cancer in order to identified new therapeutic targets. She is now focused on triple-negative breast tumor, studying the role tumor suppressor of claudin 1, a tight junction protein.